Trial Profile
Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Real-World Patient Population in China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Apr 2018
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms R-C Registry
- Sponsors Medtronic
- 23 Nov 2013 Status changed from active, no longer recruiting to completed according to results published in the American Journal of Cardiology.
- 23 Apr 2013 Planned end date changed from 1 Jul 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.